Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX + Sintilimab + HBOT in Advanced Gastric/GEJ Cancer
NCT06742411Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Started Dec 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06742411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742411.